Advanced Pharma Recalls NOVA PeriCapsular Injection for Latex Labeling
Advanced Pharma Inc. is recalling NOVA PeriCapsular injection because the product may contain synthetic or natural latex, which is not clearly labeled.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and involves a labeling error regarding potential latex content, which fits the criteria for minor labeling errors or low-risk contamination.
Plain-English summary
Advanced Pharma Inc. is voluntarily recalling NOVA PeriCapsular injection, all strengths, all dosage forms, and all packaging. The recall is being conducted because the product may contain synthetic latex and/or natural latex, and this information is not adequately classified in the labeling.
The recall covers all lots of the product, which is distributed nationwide in the United States. The product is prescription-only and is distributed by Avella of Houston in Houston, Texas.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or the recalling firm for further instructions. This recall addresses a labeling issue regarding potential latex content.
The recalled product
- Product
- NOVA PeriCapsular injection all strengths, all dosage forms and all packaging, Rx Only, Avella of Houston, Houston, TX 77054
- Manufacturer
- Advanced Pharma Inc.
- Category
- Drug — Injection
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- all lots
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 60 recalled by Advanced Pharma Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 60 products in this recall →Related recalls
Same manufacturer · Advanced Pharma Inc.
See all →- HighAdvanced Pharma Recalls Sub-Potent Hydromorphone Injectable Solution
FDA (Drugs) · 2019-05-08
- SevereAdvanced Pharma Recalls Lidocaine Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-03-27
- HighAdvanced Pharma Recalls Glycopyrrolate Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-03-27
- SevereAdvanced Pharma Recalls Heparin Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-03-27
- SevereAdvanced Pharma Recalls Phenylephrine HCl Injectable Solution Due to Sterility Concerns
FDA (Drugs) · 2019-03-27
Same hazard · latex allergen
See all →- ModerateHalyard Laparoscopy Comprehensive Pack II Recalled for Latex Content
FDA (Devices) · 2026-10-14
- ModerateAVID Medical Recalls Halyard Total Joint Kits Due to Latex Labeling Error
FDA (Devices) · 2026-09-02
- ModerateAVID Medical Recalls Halyard Total Joint Kits for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
- ModerateHalyard Total Joint Kits Recalled for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
- ModerateAVID Medical Recalls Halyard Total Joint Kits for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
Similar recalls
- ModerateAdvanced Pharma Recalls Oxytocin Injectable Solution Due to Superpotency
FDA (Drugs) · 2019-02-27
- LowAdvanced Pharma Recalls Oxytocin Injectable Solution Due to Superpotent Drug Concerns
FDA (Drugs) · 2019-02-27
- SevereAdvanced Pharma Recalls Neostigmine Methylsulfate Injection Due to Sterility Concerns
FDA (Drugs) · 2019-03-27
- ModerateHeparin Injectable Solution Recalled for Incorrect Concentration Labeling
FDA (Drugs) · 2019-01-30
- HighAdvanced Pharma Recalls Sub-Potent Hydromorphone Injectable Solution
FDA (Drugs) · 2019-05-08
- SevereAdvanced Pharma Recalls Lidocaine Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-03-27